{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:45:51Z","timestamp":1789908351221,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jhep.2015.04.009","type":"journal-article","created":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T04:30:28Z","timestamp":1429331428000},"page":"564-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent"],"prefix":"10.1016","volume":"63","author":[{"given":"Xavier","family":"Forns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Palcza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Y.M.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"DiNubile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliav","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.04.009_b0005","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","article-title":"Current and future therapies for hepatitis C virus infection","volume":"368","author":"Liang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.04.009_b0010","unstructured":"American Association for the Study of Liver Diseases, Infectious Disease Society of North America. Recommendations for testing, managing, and treating hepatitis C. Available at: <http:\/\/www.hcvguidelines.org> (accessed 1 March 2015)."},{"key":"10.1016\/j.jhep.2015.04.009_b0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.04.009_b0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11894-011-0237-1","article-title":"Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors","volume":"14","author":"Gambarin-Gelwan","year":"2012","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhep.2015.04.009_b0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2015.04.009_b0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.04.009_b0035","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2015.04.009_b0040","first-page":"1","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4a protease inhibitors","volume":"2012","author":"Romano","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2015.04.009_b0045","doi-asserted-by":"crossref","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"Ribeiro","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2015.04.009_b0050","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.coviro.2012.08.008","article-title":"Clinical relevance of HCV antiviral drug resistance","volume":"2","author":"Welsch","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhep.2015.04.009_b0055","doi-asserted-by":"crossref","first-page":"e39652","DOI":"10.1371\/journal.pone.0039652","article-title":"HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"Cento","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.04.009_b0060","unstructured":"HCV DrAG Phenotype and Sequence Analysis Working Group. Ann Forum Collab HIV Res. Available at <http:\/\/www.idsociety.org\/uploadedFiles\/IDSA\/Hepatitis_C\/For_IDSA_Members\/ForumforCollaborativeHIV-ClinicallyRelevantHCVDrug.pdf> (accessed 12 December 2014)."},{"key":"10.1016\/j.jhep.2015.04.009_b0065","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.04.009_b0070","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.04.009_b0075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.04.009_b0080","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.04.009_b0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.04.009_b0090","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.04.009_b0095","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"Howe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.04.009_b0100","first-page":"120","article-title":"Analysis of heterogeneous viral populations by direct DNA sequencing","volume":"15","author":"Leitner","year":"1993","journal-title":"Biotechniques"},{"key":"10.1016\/j.jhep.2015.04.009_b0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-62703-484-5_12","article-title":"Amplification and sequencing of the hepatitis C virus NS3\/4a protease and the NS5b polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b","volume":"1030","author":"Koletzki","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhep.2015.04.009_b0110","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.jhep.2015.04.009_b0115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bouli\u00e8re","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.04.009_b0120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(15)70094-0","article-title":"Hope for non-responders with hepatitis C virus and cirrhosis","volume":"15","author":"Dusheiko","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.04.009_b0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1128\/JCM.02371-13","article-title":"Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection","volume":"52","author":"Akuta","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2015.04.009_b0130","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/hep.24791","article-title":"Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment","volume":"55","author":"Harrington","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.04.009_b0135","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/hep.25888","article-title":"Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents","volume":"56","author":"Wedemeyer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.04.009_b0140","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","article-title":"Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies","volume":"144","author":"Chen","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.04.009_b0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.04.009_b0150","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/ciu865","volume":"60","author":"Poordad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.04.009_b0155","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.04.009_b0160","author":"Sulkowski","year":"2015","journal-title":"Lancet"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815002913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815002913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T06:24:16Z","timestamp":1537683856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815002913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0168827815002913"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.04.009","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725442388.793506334","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}